Glecaprevir API CAS 1365970-03-1

Glecaprevir API CAS 1365970-03-1 is a second-generation HCV NS3/4A protease inhibitor and a core direct-acting antiviral (DAA) for the treatment of chronic hepatitis C. It targets the NS3/4A protease, which is essential for HCV replication, and blocks the cleavage and maturation of viral polyproteins, thus inhibiting viral replication at its source. Compared with first-generation inhibitors, it has 100 times greater inhibitory activity, a higher resistance barrier, and covers all HCV genotypes 1-6.

Glecaprevir is a landmark product in the treatment of hepatitis C. With its core advantages of pan-genotypic therapy, short treatment duration, and high cure rate, it has reshaped the global landscape of hepatitis C treatment, possessing clinical, industrial, and public health value. Its comprehensive lifecycle strategy, from R&D and patents to the market, has become a classic case study for multinational pharmaceutical companies in the antiviral field. While its market structure will further evolve with patent expiration and domestic substitution, its industry position as a core product for hepatitis C cure will remain stable in the long term.